The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Current therapies for advanced HCC and their limitations
The hepatocellular carcinoma (HCC) treatment landscape has expanded in all settings, with multi-kinase and immune checkpoint inhibitors taking center stage. At the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, discusses the efficacy and limitations of emerging agents such as bevacizumab, regorafenib and lenvatinib, as well as their role in disease biology and combination regimens.
